scholarly journals Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature

2018 ◽  
Vol Volume 11 ◽  
pp. 1239-1245 ◽  
Author(s):  
Nicoletta Cinone ◽  
Sara Letizia ◽  
Luigi Santoro ◽  
Michele Gravina ◽  
Loredana Amoruso ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Shoulder Pain ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Review Of The Literature ◽  
Glenohumeral Osteoarthritis

scholarly journals Hemiplegic shoulder pain: Comparison of two sites of intramuscular injections of botulinum toxin type A, “epautox” study

2016 ◽  
Vol 59 ◽  
pp. e72 ◽  
Author(s):  
Sophie Larrazet ◽  
Romain Joste ◽  
Angélique Stefan ◽  
Anne Delaubier ◽  
André Gueyraud ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Shoulder Pain ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Intramuscular Injections

scholarly journals Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaurav Verma
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Review Of The Literature ◽  
The Past ◽  
Permanent Cure ◽  
Variable Success

Trigeminal neuralgia (TN) is a clinical condition characterized by paroxysmal attacks of severe and electric shock-like pain along the distribution of one or more branches of the trigeminal nerve. Various medicinal or surgical modalities have been employed in the past with variable success. Newer methods were tried in search of permanent cure or long-lasting pain relief. The purpose of this paper is to present the review of the literature regarding the use of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia.

Efficacy of Intra-Articular Injection of Botulinum Toxin Type A in Refractory Hemiplegic Shoulder Pain

2011 ◽  
Vol 92 (7) ◽  
pp. 1034-1037 ◽  
Author(s):  
Alberto Castiglione ◽  
Sergio Bagnato ◽  
Cristina Boccagni ◽  
Marcello C. Romano ◽  
Giuseppe Galardi
Keyword(s):  
Botulinum Toxin ◽  
Shoulder Pain ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals «Off-label» use of botulinic toxin type A preparations in neurological practice

2018 ◽  
Vol 20 (2) ◽  
pp. 195-201
Author(s):  
L R Akhmadeeva ◽  
Kh P Derevyanko
Keyword(s):  
Botulinum Toxin ◽  
Therapeutic Option ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Off Label Use ◽  
Off Label ◽  
Positive Effects ◽  
Label Use

The modern view on the application of botulinum toxin type A for the off-label use in neurology and foreign experience analysis are presented. The «off-label» category referred to any prescription of a medication in case of using it for unregistered indications, with product instruction violation or in the presence of contraindications including age restrictions. The sources of information about medicines were the leaflets of manufacturers of medicines and the State Register of Medicines. It is well known that Botulinum toxin type A is a good therapeutic option for treating children with cerebral palsy. Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in medication-overuse headache patients beyond the first year of treatment. Botulinum toxin type A is effective in the management of sialorrhea. Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction. Facing depression with botulinum toxin: positive effects on mood have been observed in subjects who underwent treatment of glabellar frown lines with botulinum toxin and, in an open case series, depression remitted or improved after such a treatment. Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson’s disease with deep brain stimulation. The paper describes the problems associated with the lack of clinical data about the possibility of using botulinum toxin type A in different conditions, emphasizes the need to organize clinical trials and educational programs for neurologists as well as more active implementation of protocols for the treatment of patients.

scholarly journals Pregnancy outcomes following botulinum toxin type A exposure: A systematic review

2018 ◽  
Vol 6 (05) ◽  
Author(s):  
Noha Abdelkader ◽  
Elif Keskin Arslan ◽  
Hilal Erol- Coskun ◽  
Gözde Küçüksolak ◽  
Yusuf Cem Kaplan
Keyword(s):  
Botulinum Toxin ◽  
Pregnancy Outcomes ◽  
Congenital Malformations ◽  
Case Reports ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Fetal Loss ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Major Congenital Malformations

Objective: To evaluate the available human data to-date in order to assess whether the prenatal exposure to botulinum toxin type A (BTX-A) is associated with major congenital malformations and other adverse pregnancy outcomes. Methods: Searches were conducted in PubMed/MEDLINE and Reprotox in November  2017. Cohort and case-control studies, case series, case reports were the primary data of interest. Results: No controlled studies but case series and case reports of therapeutic BTX-A administration during pregnancy were identified. Case reports regarding pregnant women with botulism were also reviewed. Conclusions: Limited data suggests that BTX-A exposure for therapeutic indications during pregnancy does not seem to be associated with an increase in risk of major congenital malformations. Rates of fetal loss were substantially different between prospective and retrospective data. Controlled epidemiological studies are needed to refute or support our findings.

Sign in / Sign up

Export Citation Format

Share Document